Master Class Series

Introducing: Master Class Series on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Amyloidosis News is pleased to introduce a Master Class Series on Transthyretin Amyloid Cardiomyopathy (ATTR-CM). This series, consisting of 5 half-hour virtual programs, is designed to provide disease state education on ATTR-CM, a rare, life-threatening, underrecognized, and underdiagnosed type of amyloidosis that is associated with heart failure.

The virtual programs will feature amyloidosis specialists in roundtable discussions surrounding ATTR-CM. You will have an opportunity to participate in live Q&A after each session.

Subscribe to receive virtual program updates.


Supported by


Master Class Program 2: Maximal TTR Stabilization: Early Treatment, Better Outcomes

Thursday, Nov 11, 12:00 - 12:30pm ET

In this roundtable discussion, transthyretin amyloidosis specialists will convey the opportunity for improved patient outcomes with early intervention of stabilizer therapy.

Topics of discussion:

  • Impact of untreated ATTR-CM
  • ATTR-CM diagnosis
  • Potential impact of early ATTR-CM diagnosis

Panelists include:

Interview with the Innovators

Robert Townsend Cole, MD, FHFSA
Medical Director, Advanced Heart Failure, Cardiac Transplant, and LVAD
Director, Heart Failure and Cardiac Transplant Research
Samsky Advanced Heart Failure Center
Piedmont Heart Institute
Atlanta, GA

Interview with the Innovators

Brett W. Sperry, MD
Associate Professor of Medicine
Director of Cardiac Amyloidosis Program
Saint Luke’s Mid America Heart Institute
Kansas City, MO

Interview with the Innovators

Joban Vaishnav, MD
Assistant Professor of Medicine
Advanced Heart Failure & Transplant Cardiology
Johns Hopkins Hospital
Baltimore, MD




Previous Master Classes in this Series.

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: